Obturator Nerve Block with Botulinum Toxin Type B for Patient with Adductor Thigh Muscle Spasm -A Case Report- |
Choi, Eun-Joo
(Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
Byun, Jong-Min (Seoul National University College of Medicine) Nahm, Francis Sahng-Un (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) Lee, Pyung-Bok (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) |
1 | Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Semin Cutan Med Surg 2001; 20: 127-36. DOI |
2 | Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-7. DOI ScienceOn |
3 | Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005; 20: 1152-60. DOI ScienceOn |
4 | Callaway JE. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 2004; 22: 23-8. |
5 | Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-7. |
6 | Akkaya T, Unlu E, Alptekin A, Gumus HI, Umay E, Cakci A. Neurolytic phenol blockade of the obturator nerve for severe adductor spasticity. Acta Anaesthesiol Scand 2010; 54: 79-85. DOI ScienceOn |
7 | Al-Saleem FH, Ancharski DM, Ravichandran E, Joshi SG, Singh AK, Gong Y, et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 2008; 326: 856-63. DOI ScienceOn |
8 | Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62: 705-22. DOI ScienceOn |
9 | Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003; 21: 476-80. DOI ScienceOn |
10 | Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-9. DOI ScienceOn |
11 | Kharkar S, Ambady P, Yedatore V, Schwartzman RJ. Intramuscular botulinum toxin A (BtxA) in complex regional pain syndrome. Pain Physician 2011; 14: 311-6. |
12 | Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-9. DOI |
13 | Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des 2009; 15: 3671-80. DOI ScienceOn |
14 | Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol 2009; 10: 87-102. DOI ScienceOn |
15 | Lim SJ, Park HJ, Lee SH, Moon DE. Ganglion impar block with botulinum toxin type a for chronic perineal pain -a case report-. Korean J Pain 2010; 23: 65-9. DOI |
16 | Calderon-Gonzalez R, Calderon-Sepulveda RF. Clinical treatment (non surgical) of spasticity in cerebral palsy. Rev Neurol 2002; 34: 1-6. |
17 | O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain 2002; 18(6 Suppl): S182-90. DOI |
18 | Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28: 140-75. DOI ScienceOn |
19 | Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005; 53: 3-9. |
20 | Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2. |